U.S. approves new drug addressing type 1 diabetes

The U.S. Food and Drug Administration (FDA) has recently approved a new therapy that slows the onset of type 1 diabetes.

"It targets one of the root causes of this type of diabetes and can slow the onset of the disease. Better still, the drug could be the herald of a new era in treating the condition," said a podcast of The Economist on Tuesday.

The drug, named Tzield, was authorized by the FDA to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Tzield binds to certain immune system cells and delays progression to stage 3 type 1 diabetes, according to the FDA. Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the immune response.

The drug is administered by intravenous infusion once daily for 14 consecutive days. dirt bike girl bikini.